October 12, 2010

HELIX BIOPHARMA COMPLETES DEFINITIVE GLP TOXICOLOGY STUDIES WITH L-DOS47 AND IS MAKING FINAL PREPARATIONS FOR ITS PLANNED PHASE I/II CLINICAL STUDY IND/CTA SUBMISSIONS (PDF)

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”) today announced that it has
completed its definitive GLP, rodent and primate, repeat-dose toxicology studies with L-DOS47. These studies
demonstrated a good safety profile in an expanded number of rodent and primate test animals, building upon
Helix’s positive findings from its preliminary non-GLP toxicology studies.